A terminally ill cancer patient in the United States, who was formerly employed as a school groundskeeper, is testifying in court that working with Monsanto’s Roundup weed killer caused him to develop non-Hodgkin’s lymphoma.
While Monsanto has recently been bought by the pharmaceutical and chemical giant Bayer, its already considerable legal problems are continuing to mount. As recently as a year ago there were more than 800 patients known to be suing Monsanto and ready to testify that Roundup had caused them to develop cancer. Today, however, Timothy Litzenburg, the attorney for the terminally ill groundskeeper who is testifying against Monsanto, says he now represents more than 2,000 non-Hodgkin’s lymphoma sufferers who, prior to their diagnosis, had been using the weed killer “extensively”.
Glyphosate, the key ingredient in Roundup, has already been cited by the World Health Organization’s International Agency for Research on Cancer (IARC) as being “probably carcinogenic to humans.” In a monograph published in March 2015, IARC specifically noted that its classification of the chemical had followed a “comprehensive review of the latest available scientific evidence”. Later, in a study published in 2017, scientists at the Dr. Rath Research Institute further confirmed the damaging effects of glyphosate on cells and described how speciﬁc micronutrients applied in proper combinations and dosages can provide some protective eﬀects against it. Not only was this research essentially ignored, evidence has emerged that Monsanto had seemingly manipulated studies on Roundup to conceal its risks.
While Bayer itself was already no stranger to controversy, by purchasing Monsanto it has simultaneously bought itself a whole host of additional problems. The Monsanto name may soon be no more, but its toxic after-effects will doubtless live on for many years to come.